Literature DB >> 9453053

Recombinant factor VIII SQ--inactivation kinetics in aqueous solution and the influence of disaccharides and sugar alcohols.

A Fatouros1, T Osterberg, M Mikaelsson.   

Abstract

PURPOSE: To investigate the influence of various nonreducing disaccharides and sugar alcohols on the inactivation kinetics of recombinant factor VIII SQ (r-VIII SQ) in aqueous solution not containing albumin as a stabiliser.
METHODS: The stability of r-VIII SQ was followed using measurement of activity (VIII:C) and HPLC gel filtration at different temperatures. The thermal stability was investigated using differential scanning calorimetry (DSC).
RESULTS: The decline in VIII:C followed pseudo-first order kinetics. However, the Arrhenius plot was not linear for formulations without carbohydrate, demonstrating a distinct, reproducible curvature. The reaction rate at 5 degrees C was faster than expected from the Arrhenius kinetics. The energy of activation (Ea) for formulations without added carbohydrates, derived from the linear part of the Arrhenius plot, varied between 77 and 86 kJ/mole in the temperature range 20-37 degrees C. The addition of 600 mg/ml sucrose increased the Ea to 104 kJ/mole. DSC measurements showed that Tm' was 64.2 +/- 0.2 degrees C for r-VIII SQ without stabiliser. This value increased linearly with increasing concentrations of carbohydrate. This stabilising effect is most probably explained by the theory of preferential hydration.
CONCLUSIONS: The inactivation kinetics of r-VIII SQ in aqueous solution without addition of carbohydrates followed pseudo-first order kinetics but the Arrhenius plot was nonlinear. Sucrose and sorbitol both had highly stabilising effects on r-VIII SQ at concentrations above 300 mg/ml. The preparation containing 600 mg/ml sucrose was stable for at least 12 months at 5 degrees C and 6 months at 25 degrees C.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9453053     DOI: 10.1023/a:1012163309468

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

Review 1.  Pharmaceutics of protein drugs.

Authors:  R Pearlman; T Nguyen
Journal:  J Pharm Pharmacol       Date:  1992-02       Impact factor: 3.765

Review 2.  Conformational stability of globular proteins.

Authors:  C N Pace
Journal:  Trends Biochem Sci       Date:  1990-01       Impact factor: 13.807

3.  Osmolalities of commercially supplied drugs often used in anesthesia.

Authors:  H Bretschneider
Journal:  Anesth Analg       Date:  1987-04       Impact factor: 5.108

4.  The mechanisms of irreversible enzyme inactivation at 100C.

Authors:  T J Ahern; A M Klibanov
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

5.  Calorimetric study on thermal denaturation of lysozyme in polyol-water mixtures.

Authors:  K Gekko
Journal:  J Biochem       Date:  1982-04       Impact factor: 3.387

6.  Stabilization of protein structure by sugars.

Authors:  T Arakawa; S N Timasheff
Journal:  Biochemistry       Date:  1982-12-07       Impact factor: 3.162

Review 7.  Factor VIII structure and function.

Authors:  P A Foster; T S Zimmerman
Journal:  Blood Rev       Date:  1989-09       Impact factor: 8.250

8.  Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ.

Authors:  T Osterberg; A Fatouros; M Mikaelsson
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

9.  Increased thermal stability of proteins in the presence of sugars and polyols.

Authors:  J F Back; D Oakenfull; M B Smith
Journal:  Biochemistry       Date:  1979-11-13       Impact factor: 3.162

10.  Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.

Authors:  P Lind; K Larsson; J Spira; M Sydow-Bäckman; A Almstedt; E Gray; H Sandberg
Journal:  Eur J Biochem       Date:  1995-08-15
View more
  4 in total

1.  Correlation of rFVIII inactivation with aggregation in solution.

Authors:  Wei Wang; Drew N Kelner
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

2.  Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII).

Authors:  Karthik Ramani; Vivek S Purohit; Razvan D Miclea; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2005-06       Impact factor: 3.534

3.  Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.

Authors:  Bei Chen; Raquel Bautista; Kwok Yu; Gerardo A Zapata; Michael G Mulkerrin; Steven M Chamow
Journal:  Pharm Res       Date:  2003-12       Impact factor: 4.200

4.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.